IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
← Leaderboard
DGX
Ticker

DGX

Congressional Trades
14
by 5 members
Ticker Intelligence Brief

Who in Congress traded DGX, when, and what happened after?

A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.

Latest receipt
Ro Khanna
SELL · 2026-02-17
Largest range
$15K – $50K
Tommy Tuberville
Slowest filing
261d
Julia Letlow
Best vs SPY
15.9%
Ro Khanna
Buys
7
50%
Sells
6
43%
Total Volume
$137K
midpoint
Unique Traders
5
members

Party Breakdown

Democrats7 · 50%
Republicans7 · 50%

Party Trading Divergence

Democrat vs. Republican buy / sell pressure by monthMODERATE

Bar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.

Democrat ←
Month
→ Republican
—
Jan '24
0▲1▼
2▲
Nov '24
—
1▲
Jan '25
—
—
Mar '25
0▲1▼
—
Apr '25
2▲
—
Jul '25
0▲2▼
0▲2▼
Nov '25
—
1▲
Jan '26
—
0▲1▼
Feb '26
—
Democrats4▲3▼Net buyers
vs
Republicans2▲4▼Net sellers
Net buyingNet selling⚡ Party split

🏛️ Federal Contracts

all →
  • 2026-06-16$5K
    Department of Justice
    QUEST FY26 MEDICAL B1 LAB TESTING FOR INMATES BPA 15BNAS26A00000038 V797D 70090 THE NEW PERIOD OF PERFORMANCE IS JANUARY 1 2026 MARCH 31 2026
  • 2026-06-11$15K
    Department of Justice
    FY26 B5 QUEST LAB TESTING MAY 26 SCHEDULE NUMBER: V797D-70090
  • 2026-06-09$10K
    Department of Justice
    LABS FOR INMATE POPULATION FOR FCI/FPC BECKLEY WV 3RD QTR FY2026
  • 2026-06-09$3K
    Department of Justice
    FY26 B1 QUEST LABS APRIL QTR 3
  • 2026-06-02$11K
    Department of Justice
    FY26 B1 QUEST INMATE LABS MAY26
  • 2026-06-01$475K
    Department of Health and Human Services
    BASE PERIOD-FEDERAL OCCUPATIONAL HEALTH CLINICAL LABORATORY TESTING SERVICES PERIOD OF PERFORMANCE: 6/20/2026-12/19/2026
  • 2026-06-01$2K
    Department of Justice
    BRIDGE CONTRACT REQUEST TO COVER OPTION #2 MAY 1-MAY 31. RP #26-0148
  • 2026-05-28$2K
    Department of Justice
    FCI THREE RIVERS LABORATORY TESTING SERVICES FY26
  • 2026-05-28$2K
    Department of Justice
    FCI THREE RIVERS LABORATORY TESTING SERVICES FY26 APRIL
  • 2026-05-26$67K
    Department of Veterans Affairs
    RESEARCH SPECIMEN ANALYSIS SERVICES.

💼 Lobbying Filings

all →
  • 2026-04-20$690K
    QUEST DIAGNOSTICS INCORPORATED
    Federal policy related to strengthening the clinical laboratory workforce S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act H.R. 6130 - Alzheimers Screening and Prevention Act of 2025 Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program
  • 2026-04-20$80K
    QUEST DIAGNOSTICS INCORPORATED
    Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests. H.R. 7148 - Consolidated Appropriations Act, 2026 - issues related to clinical lab test reimbursement rates.
  • 2026-04-20$60K
    QUEST DIAGNOSTICS
    diagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain physician fee schedule, savings access to lab services federal budget issues
  • 2026-04-20$50K
    QUEST DIAGNOSTICS INCORPORATED
    Issues related to patient access and affordability of clinical laboratory testing. Issues related to the FY2026 budget and appropriations process Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act
  • 2026-01-20$350K
    QUEST DIAGNOSTICS INCORPORATED
    Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation S. 2355 and H.R. 5582 - Patients Deserve Price Tags Act S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 Diagnostics and chronic disease prevention and treatment S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Regulatory changes to Sec. 216 of the Protecting Access to Medicare Act of 2014 (PAMA)
  • 2026-01-20$330K
    QUEST DIAGNOSTICS INCORPORATED
    Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation Federal price transparency legislation related to clinical laboratories S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 P.L. 118-22/H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024, provisions related to Medicare reimbursement for clinical diagnostics and pathology laboratory services Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Appropriations related to clinical laboratory workforce, PFAS and cardiovascular disease testing
  • 2026-01-20$310K
    QUEST DIAGNOSTICS INCORPORATED
    Federal policy and programs regarding oncology research and development related to cancer screening, diagnosis, and survivorship Federal policy related to strengthening the clinical laboratory workforce Food and Drug Administration (FDA) policies related to diagnostics and laboratory regulation Federal price transparency legislation related to clinical laboratories S.1816/H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 H.R. 5571 - Expanding Seniors Access to PFAS Testing Act S.2761 and H.R. 5269, the Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 P.L. 118-22/H.R. 6363 - Further Continuing Appropriations and Other Extensions Act, 2024, provisions related to Medicare reimbursement for clinical diagnostics and pathology laboratory services Federal policy related to coverage and reimbursement of clinical laboratory services under the Medicare program Appropriations related to clinical laboratory workforce, PFAS and cardiovascular
  • 2026-01-20$80K
    QUEST DIAGNOSTICS INCORPORATED
    Policies, rules, and regulations related to clinical laboratories and Medicare coverage policies. H.R.5269 - Reforming and Enhancing Sustainable Updates to Laboratory Testing Services (RESULTS) Act - Issues related to Medicare payments for lab tests. S.2761 - RESULTS Act - Issues related to Medicare payments for lab tests.
  • 2026-01-20$60K
    QUEST DIAGNOSTICS
    diagnostics, clinical lab reimbursement issues, savings access to lab service, supply chain physician fee schedule, savings access to lab services federal budget issues
  • 2026-01-20$50K
    QUEST DIAGNOSTICS INCORPORATED
    Issues related to patient access and affordability of clinical laboratory testing. Issues related laboratory data collection and reimbursement under PAMA. H.R. 5269 - RESULTS Act S. 2761 - RESULTS Act Issues related to patient access and affordability of clinical laboratory testing. Issues related to the FY2026 budget and appropriations process

Congressional Momentum

buy vs. sell pressureDISTRIBUTING

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days
No trades
Last 90 Days
No trades
All-Time
▼41
7 buys14 total7 sells
$56K buys · $81K sells
Cumulative Net Position (buy vol − sell vol)
-$25K
2021-0314 trades plotted2026-02

Best Timers

avg excess return vs SPY · DGX trades only4 members w/ alpha data

Excess return = stock price change minus SPY change over the same holding window.Congress avg: +1.0%· 50% of traders beat SPY on this name

Top Alpha Generators
D:2R:2House:4
underperformed SPY|beat SPY
1st
D
Julie Johnson
+10.0%
1×
2nd
D
Ro Khanna
+6.6%
5×
3rd
R
Julia Letlow
-3.5%
2×
4th
R
Carol Miller
-9.0%
1×
Worst Timers
bottom 4 by avg excess return
underperformed SPY|beat SPY
R
Carol Miller
-9.0%
1×
R
Julia Letlow
-3.5%
2×
D
Ro Khanna
+6.6%
5×
D
Julie Johnson
+10.0%
1×
Worst single trade: Julia Letlow (-13.7%)Best single trade: Ro Khanna (+15.9%)

Timing Fingerprint

filing delay vs. excess return over SPY · 9 tradesCongress avg +3.0% vs SPY

Each dot = one disclosed trade. X-axis = days between trade and STOCK Act filing.Y-axis = return above (or below) SPY over the subsequent holding window. Upper-right = late filers who beat the market.

LATE + BEAT SPY2 tradesQUICK + BEAT SPY4 tradesQUICK + TRAILEDLATE + TRAILED-18%-9%0%+9%+18%median 23d0d55d110d165d220dRo Khanna (D) · 2026-02-17 · sell · 20d delay · -4.9% vs SPY · $8KRo Khanna (D) · 2026-01-29 · buy · 8d delay · +9.4% vs SPY · $8KJulie Johnson (D) · 2025-11-03 · sell · 38d delay · +10.0% vs SPY · $8KJulia Letlow (R) · 2025-07-24 · sell · 173d delay · +6.6% vs SPY · $8KJulia Letlow (R) · 2025-04-28 · buy · 260d delay · -13.7% vs SPY · $8KCarol Miller (R) · 2025-03-10 · sell · 32d delay · -9.0% vs SPY · $8KRo Khanna (D) · 2025-01-17 · buy · 20d delay · +15.9% vs SPY · $8KRo Khanna (D) · 2024-11-15 · buy · 20d delay · +5.7% vs SPY · $8KRo Khanna (D) · 2024-11-12 · buy · 23d delay · +7.0% vs SPY · $8KFiling Delay (days)Excess Return vs SPY
67% of trades beat SPYavg excess +3.0%avg delay 66d5 buys4 sellsBuySellOther· dot size ∝ trade size

Trade Activity Timeline

Congressional buys & sells by month · last 10 months w/ activity

21/03
24/01
24/11
25/01
25/03
25/04
25/07
25/11
26/01
26/02
BuysSellsOtherHigh-volume month

Who Moved First

each row = one member · sorted by earliest disclosed trade
3 buyers ·5 sellers
202420252026RTommy Tuberville2×2021-03-29 · buy · $8K2024-01-03 · partial_sell · $33KDRo Khanna5×2024-11-12 · buy · $8K2024-11-15 · buy · $8K2025-01-17 · buy · $8K2026-01-29 · buy · $8K2026-02-17 · sell · $8KRCarol Miller1×2025-03-10 · sell · $8KRJulia Letlow4×2025-04-28 · buy · $8K2025-04-28 · buy · $8K2025-07-24 · sell · $8K2025-07-24 · sell · $8KDJulie Johnson2×2025-11-03 · sell · $8K2025-11-03 · sell · $8K
BuySellOtherDot size ∝ trade size · top 5 most-active traders shown

Seasonal Rhythm

Congress buy/sell pressure by month & year

Each cell = one calendar month. Green = net Congress buying, red = net selling. Intensity ∝ consensus strength. Hover for details.

JanFebMarAprMayJunJulAugSepOctNovDec20262026-01: 1▲ 0▼ · $0.0M12026-02: 0▲ 1▼ · $0.0M12026-03: 0▲ 0▼2026-04: 0▲ 0▼2026-05: 0▲ 0▼2026-06: 0▲ 0▼2026-07: 0▲ 0▼2026-08: 0▲ 0▼2026-09: 0▲ 0▼2026-10: 0▲ 0▼2026-11: 0▲ 0▼2026-12: 0▲ 0▼20252025-01: 1▲ 0▼ · $0.0M12025-02: 0▲ 0▼2025-03: 0▲ 1▼ · $0.0M12025-04: 2▲ 0▼ · $0.0M22025-05: 0▲ 0▼2025-06: 0▲ 0▼2025-07: 0▲ 2▼ · $0.0M22025-08: 0▲ 0▼2025-09: 0▲ 0▼2025-10: 0▲ 0▼2025-11: 0▲ 2▼ · $0.0M22025-12: 0▲ 0▼20242024-01: 0▲ 1▼ · $0.0M12024-02: 0▲ 0▼2024-03: 0▲ 0▼2024-04: 0▲ 0▼2024-05: 0▲ 0▼2024-06: 0▲ 0▼2024-07: 0▲ 0▼2024-08: 0▲ 0▼2024-09: 0▲ 0▼2024-10: 0▲ 0▼2024-11: 2▲ 0▼ · $0.0M22024-12: 0▲ 0▼20212021-01: 0▲ 0▼2021-02: 0▲ 0▼2021-03: 1▲ 0▼ · $0.0M12021-04: 0▲ 0▼2021-05: 0▲ 0▼2021-06: 0▲ 0▼2021-07: 0▲ 0▼2021-08: 0▲ 0▼2021-09: 0▲ 0▼2021-10: 0▲ 0▼2021-11: 0▲ 0▼2021-12: 0▲ 0▼
Net buyingNet sellingNo trades · number = trade count
Peak buy month: Jan · Peak sell month: Jul

Congressional Conviction Timeline

net positioning · alpha track recordMIXED
7 buys7 sellscumulative α +24.4%10mo tracked
Monthly Net Flow (Buys − Sells)
+2-202021-03: +1 net (1B / 0S)2024-01: -1 net (0B / 1S)2024-11: +2 net (2B / 0S)2025-01: +1 net (1B / 0S)2025-03: -1 net (0B / 1S)2025-04: +2 net (2B / 0S)2025-07: -2 net (0B / 2S)2025-11: -2 net (0B / 2S)2026-01: +1 net (1B / 0S)2026-02: -1 net (0B / 1S)Mar 21Nov 24Mar 25Jul 25Jan 26
Cumulative Excess Return on Congressional Buys vs SPY
+24.4%29%0%0%

All Disclosed Trades

DateMemberActionAmountFiling DelayReceipt
2026-02-17DRo KhannaSELL$1K – $15K20dreceipt →
2026-01-29DRo KhannaBUY$1K – $15K8dreceipt →
2025-07-24RJulia LetlowSELL$1K – $15K174dreceipt →
2025-04-28RJulia LetlowBUY$1K – $15K261dreceipt →
2025-07-24RJulia LetlowSELL$1K – $15K173dreceipt →
2025-04-28RJulia LetlowBUY$1K – $15K260dreceipt →
2025-11-03DJulie JohnsonSELL$1K – $15K39dreceipt →
2025-11-03DJulie JohnsonSELL$1K – $15K38dreceipt →
2025-03-10RCarol MillerSELL$1K – $15K32dreceipt →
2025-01-17DRo KhannaBUY$1K – $15K20dreceipt →
2024-11-15DRo KhannaBUY$1K – $15K20dreceipt →
2024-11-12DRo KhannaBUY$1K – $15K23dreceipt →
2024-01-03RTommy TubervillePARTIAL_SELL$15K – $50K43dreceipt →
2021-03-29RTommy TubervilleBUY$1K – $15K882dreceipt →